New Stock News | Bairui Kang is reportedly considering an IPO in Hong Kong

According to media reports, the pharmaceutical company Bioliscon is considering an IPO in Hong Kong. Bioliscon BioPharma (Hangzhou) Co., Ltd. was co-founded by a doctor with rich experience in the pharmaceutical industry in 2017 in the Qiantang district of Hangzhou, Zhejiang Province. It is a biopharmaceutical company focused on the research and industrialization of innovative anti-tumor biologics. Bioliscon has established a complete technology chain for pre-clinical research of innovative biologics, including the design and screening of lead antibodies, genetic engineering design and modification of site-specific antibody conjugates, as well as the design and screening of small molecule payloads and linkers. Through techniques such as BLI, ELISA, FACS, and internalization, the affinity, specificity, and cell-based biological activity of lead antibodies, engineered antibodies, and target proteins are identified, evaluating the ways in which antibodies are linked to payloads to form ADCs, and assessing the stability, cytotoxicity, in vivo efficacy, and safety of ADCs, ultimately developing the most promising innovative biopharmaceuticals. Since its establishment, Bioliscon has received multiple rounds of funding. For example, on April 13, 2018, they completed an angel round of tens of millions of RMB, with Eastward Rich Sea as an investor. On April 16, 2021, they completed a Series B round of 400 million RMB, with GGV Capital (led), Cormorant Asset Management, VMS Group, Charba Investment, and Eastward Rich Sea participating. On January 18, 2023, they completed a Series B+ round of 100 million RMB, with investors including NewPrint Healthcare Fund (led), Eastward Rich Sea, and Charba Investment. On June 7 of the same year, they completed a Series B++ round, with Japan's Eimatsu Pharmaceuticals as an investor.